drugset / Trial / NCT01457781
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
Timeline
- Start
- 2012-04
- Primary completion
- 2014-10
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitric Oxide | Other / unclassified | 0.025 mg/kg | Inhaled |
| Subject | Nitric Oxide | Other / unclassified | 0.075 mg/kg | Inhaled |